Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Renáta Váraljai¹, Lisa Zimmer¹, Yahya Al-Matary¹, Paulien Kaptein², Lea J Albrecht¹, Batool Shannan¹, Jan C Brase³, Daniel Gusenleitner⁴, Teresa Amaral⁵, Nina Wyss⁶, Jochen Utikal^{7

8

9}, Lukas Flatz^{5

6}, Florian Rambow^{1

10}, Hans Christian Reinhardt^{11

12}, Jenny Dick¹³, Daniel R Engel¹³, Susanne Horn^{1

14}, Selma Ugurel¹, Wiebke Sondermann¹, Elisabeth Livingstone¹, Antje Sucker¹, Annette Paschen^{1

12}, Fang Zhao¹, Jan M Placke¹, Jasmin M Klose¹⁵, Wolfgang P Fendler¹⁵, Daniela S Thommen², Iris Helfrich^{1

16}, Dirk Schadendorf^{1

12

17}, Alexander Roesch^{18

19}

Affiliations

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
² Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
⁵ Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
⁶ Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland.
⁷ Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁸ Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany.
⁹ DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
¹⁰ Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, Essen, Germany.
¹¹ Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
¹² Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.
¹³ Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
¹⁴ Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.
¹⁵ Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹⁶ Department of Dermatology and Allergology, Ludwig Maximilian University Munich, Munich, Germany.
¹⁷ NCT West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
¹⁸ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany. alexander.roesch@uk-essen.de.
¹⁹ Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.

PMID: 37580519
PMCID: PMC10518252
DOI: 10.1038/s43018-023-00632-w

Published Erratum

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Renáta Váraljai et al. Nat Cancer. 2023 Sep.

. 2023 Sep;4(9):1395.

doi: 10.1038/s43018-023-00632-w.

Authors

Affiliations

¹ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
² Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
⁵ Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
⁶ Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland.
⁷ Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁸ Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany.
⁹ DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
¹⁰ Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, Essen, Germany.
¹¹ Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
¹² Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.
¹³ Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
¹⁴ Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany.
¹⁵ Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
¹⁶ Department of Dermatology and Allergology, Ludwig Maximilian University Munich, Munich, Germany.
¹⁷ NCT West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany.
¹⁸ Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany. alexander.roesch@uk-essen.de.
¹⁹ Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.

PMID: 37580519
PMCID: PMC10518252
DOI: 10.1038/s43018-023-00632-w

No abstract available

PubMed Disclaimer

Erratum for

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.

Publication types

Actions

Grants and funding

SCHA 422/17-1 (KFO 337)/Deutsche Forschungsgemeinschaft (German Research Foundation)

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Affiliations

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Authors

Affiliations

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources